Stock Analysis

Kaisa Health Group Holdings Full Year 2024 Earnings: HK$0.009 loss per share (vs HK$0.001 profit in FY 2023)

SEHK:876
Source: Shutterstock
Advertisement

Kaisa Health Group Holdings (HKG:876) Full Year 2024 Results

Key Financial Results

  • Revenue: HK$185.4m (flat on FY 2023).
  • Net loss: HK$46.4m (down from HK$7.47m profit in FY 2023).
  • HK$0.009 loss per share (down from HK$0.001 profit in FY 2023).
We've discovered 2 warning signs about Kaisa Health Group Holdings. View them for free.
earnings-and-revenue-history
SEHK:876 Earnings and Revenue History May 5th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kaisa Health Group Holdings' share price is broadly unchanged from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Kaisa Health Group Holdings that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Kaisa Health Group Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:876

Kaisa Health Group Holdings

An investment holding company, engages in health care and dental business in the People’s Republic of China and internationally.

Flawless balance sheet and slightly overvalued.

Advertisement